0001653087false00016530872025-01-092025-01-09

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 09, 2025

 

 

Alector, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38792

82-2933343

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

131 Oyster Point Blvd.

Suite 600

 

South San Francisco, California

 

94080

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (415) 231-5660

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock

 

ALEC

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 8.01 Other Events.

Alector, Inc. (the “Company”) was developing AL002, its TREM2 program asset, to treat patients with early Alzheimer’s disease (AD) in collaboration with AbbVie Biotechnology, Ltd. (“AbbVie”) under the Co-Development and Option Agreement, dated as of October 16, 2017, between the parties, as amended on February 13, 2023 (the “AbbVie Agreement”). As announced on November 25, 2024, the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early AD did not meet its primary endpoint. On January 9, 2025, AbbVie provided written notice to the Company terminating the TREM2 program. As that program is the only remaining program under the AbbVie Agreement, such termination also terminates the AbbVie Agreement. The Company and AbbVie have agreed that such termination will be effective 30 days from the receipt of the termination letter.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ALECTOR, INC.

 

 

 

 

Date:

January 10, 2025

By:

/s/ Marc Grasso

 

 

 

Marc Grasso, M.D.
Chief Financial Officer

 

v3.24.4
Document And Entity Information
Jan. 09, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 09, 2025
Entity Registrant Name Alector, Inc.
Entity Central Index Key 0001653087
Entity Emerging Growth Company false
Entity File Number 001-38792
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 82-2933343
Entity Address, Address Line One 131 Oyster Point Blvd.
Entity Address, Address Line Two Suite 600
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (415)
Local Phone Number 231-5660
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ALEC
Security Exchange Name NASDAQ
Alector (NASDAQ:ALEC)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Alector Charts.
Alector (NASDAQ:ALEC)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Alector Charts.